Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
Provided By GlobeNewswire
Last update: Feb 13, 2025
--Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater fat loss and improvement of physical function--
Read more at globenewswire.com
